Tag: $Novo Nordisk

Novo Nordisk on Wednesday said it will offer its weight loss drug Wegovy for less than half of its usual price per month through a new direct-to-consumer online pharmacy.

Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much longer.

Danish drugmaker Novo Nordisk on Wednesday posted another quarter of rapid profit growth, though the story for once wasn’t its wildly popular weight-loss drugs.

Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share price on Friday.

Shares of Novo Nordisk jumped Friday after the Danish pharmaceutical giant reported positive early-stage results for its once weekly amycretin obesity drug.

Shares of Danish pharmaceutical giant Novo Nordisk plummeted more than 24% at one point on Friday after reporting results in a late-stage trial for its experimental CagriSema weight loss drug that missed expectations.

Eli Lilly on Wednesday said its obesity drug Zepbound led to more weight loss than its main rival, Novo Nordisk’s Wegovy, in the first head-to-head clinical trial on the weekly injections.

Novo Nordisk A/S is launching its top-selling Wegovy obesity drug in China at a fraction of the US price, a key to step in unlocking a big , fast- growing market for its blockbuster franchise 

U.S. government health plans account for the lion’s share of coverage for popular new weight-loss drugs, far beyond the reimbursement available from private employers and insurers, according to an analysis shared with Reuters.

Novo Nordisk on Wednesday reported a third-quarter beat on sales of its blockbuster weight-loss drug Wegovy and narrowed its 2024 full-year growth guidance.

The drug Liraglutide was shown in a Novo-sponsored late-stage clinical trial to have reduced the body-mass index (BMI) in children aged between 6-11.

Novo Nordisk on Wednesday posted weaker-than-expected net profit in the second quarter and trimmed its operating profit outlook.

Novo Nordisk and Eli Lilly shares slid Wednesday after Roche announced promising early-stage trial data from its latest obesity drug candidate.

Blockbuster weight loss drugs such as Wegovy and Ozempic may be associated with a rare eye condition, according to a new study released Wednesday. A Novo Nordisk spokesperson said there were “key methodological limitations” to the study

Novo Nordisk’s hugely popular weight-loss drug Wegovy has been approved in China, it said on Tuesday, the world’s second-largest economy and the country estimated to hold the highest number of overweight or obese people.

Novo Nordisk, which became the most valuable company in Europe last year due to the blockbuster success of its weight loss drugs, on Thursday beat first-quarter profit expectations as demand for those medications boomed.

The company told an investor meeting that the Phase I trial of its highly-anticipated obesity drug amycretin showed a 13.1% weight loss in participants after 12 weeks, according to Reuters.

Novo Holdings, parent of Novo Nordisk (NOVOb.CO), opens new tab, will buy contract drugmaker Catalent (CTLT.N), opens new tab for $11.5 billion in cash to help meet the strong demand for its popular weight-loss drug Wegovy, the companies said on Monday.

The maker of weight loss drug Wegovy and diabetes drug Ozempic reported an increase in sales of 31% in Danish kroner and 36% at constant exchange rates to 232.3 billion kroner ($33.71 billion).

LONDON/COPENHAGEN, Nov 10 (Reuters) – Obesity drug maker Novo Nordisk said on Friday it will spend $6 billion to boost production in Denmark, although its chief executive warned the industry was far from being able to produce enough weight-loss drugs to meet global demand.